Article Details
Retrieved on: 2024-02-17 18:02:24
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article describes the development of the ELI-002 cancer vaccine targeting KRAS mutations, showing significant T cell response and progress in a clinical trial. This relates to natural medicine by incorporating immunotherapy strategies, including virotherapy and potentially replacing CAR T cell therapy in cancer treatment.
Article found on: interestingengineering.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here